Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia
Therapeutic Apheresis, cilt.5, sa.1, ss.54-57, 2001 (Scopus)
- Yayın Türü: Makale / Özet
- Cilt numarası: 5 Sayı: 1
- Basım Tarihi: 2001
- Doi Numarası: 10.1046/j.1526-0968.2001.005001054.x
- Dergi Adı: Therapeutic Apheresis
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.54-57
- Anahtar Kelimeler: Allogeneic peripheral blood stem cell transplantation, Severe aplastic anemia
- Lokman Hekim Üniversitesi Adresli: Evet
Özet
Allogeneic peripheral blood stem cell transplantation- (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.